Stimulant Safety in ADHD Virtual Seminar

September 3, 2025

The Diversion Control Division of the Drug Enforcement Administration hosted a seminar about Stimulant Safety in ADHD on Wednesday, September 3, 2025. This conference offered DEA-registered Practitioners, Nurse Practitioners and Physician Assistants, and Pharmacists, the opportunity to meet, share information and discuss concerns regarding stimulant use, misuse and prescribing.

ADHD is the most common neurobehavioral disorder presenting for treatment. The stimulants including methylphenidate and amphetamine are among first line treatments, but the stimulants have abuse liability and the nonmedical use (NMU) including misuse and diversion has been of great interest to practitioners.

Data on the use of stimulants in ADHD, and the diversion and misuse of stimulants in those with and without a diagnosis of ADHD, were examined during this seminar.

Speakers included:

Timothy E. Wilens, MD, Chief of Child and Adolescent Psychiatry, Massachusetts General Hospital; Professor, Harvard Medical School

Sean McCabe, PhD, Director of Center for the Study of Drugs, Alcohol, Smoking and Health (DASH Center); Professor, University of Michigan

Matthew Strait, DEA Deputy Assistant Administrator

Amy Yule, MD, Vice Chair, Addiction Psychiatry, Boston Medical Center; Associate Professor, Boston University